Form 4: IN8BIO Director Corinne Epperly Reports Stock Option Grant

Director Corinne Epperly of IN8BIO, INC. reports the acquisition of stock options on December 19, 2024.

Summary

• On December 19, 2024, Corinne Epperly, a director of IN8BIO, INC., was granted stock options to purchase 37,655 shares of common stock at an exercise price of $0.24 per share.
• The options vest on December 19, 2025, contingent upon continued service to the company.
• Following the transaction, Epperly directly owns 37,655 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding stock option grants, which is generally neutral. The grant itself can be seen as a positive sign of aligning director interests with shareholders, but it's a standard practice.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service to the company.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This is a standard disclosure related to insider transactions, common in publicly traded companies. It reflects part of the compensation structure for a company director.

Stakeholder Impact

• Shareholders may view the stock option grant as a way to align the director's interests with the company's performance.
• The director benefits from the potential future value of the stock options.

Key Dates